| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |